TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Friday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $1.40 on Friday. The business has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.78. TherapeuticsMD has a 52 week low of $1.36 and a 52 week high of $3.07.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.